Strengths of this study include 1) it is one of the largest cohorts with RTX in podocytopathies; 2) it offers new insights by suggesting that pre-infusion serum albumin and proteinuria, in addition to hypertension and steroid-responsiveness, may predict clinical response to RTX; 3) it demonstrates proteinuria decrease in some steroid-resistant patients, supporting the hypothesis that RTX may have some effect in these patients; 4) most of our patients had nephrotic syndrome in T0, challenging the common belief that RTX should be used during remission to diminish urinary losses. The gene discussed is ALB; the disease is nephrotic syndrome.